Adeno-associated virus vector pharmaceutical compositions and methods
A composition and drug technology, applied in the direction of drug combination, botany equipment and method, biochemical equipment and method, etc., can solve the problems of excipient concentration, affecting supply chain and distribution, affecting the stability of biological preparations, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example 3
[0747] 5.3 Example 3: Comparison of Formulation A and Formulation B in Stability
[0748] This example shows a comparison of Formulation A and Formulation B in terms of their stability.
[0749] The new Formulation B prevented capsid rupture and release of small amounts of free DNA under freeze / thaw cycles and temperature stress. The current 12-month long-term stability study demonstrated that the in vitro relative potency and other quality attributes in FDP Formulation B were maintained at -80°C (≤-60°C) and -20°C (-25°C to -15°C).
[0750] Available freeze / thaw data, temperature stress data, and long-term stability data suggest that the new formulations have similar or improved stability.
[0751] The FDP batches in the new FDP formulation B can be set for long-term stability at -80°C (≤-60°C) and -20°C (-25°C to -15°C) and stability trend data can be used as stability planning Part of the monitoring to ensure that the expiration date of the new FDP complies with regulatio...
example 7
[0889] 5.7 Example 7: Comparison of Formulation A and Formulation B in Efficacy after 30 Freeze and Thaw Cycles
[0890] This example shows a comparison of Formulation A and Formulation B in efficacy after 30 freeze and thaw cycles.
[0891] The studies were performed by procedures similar to those shown in Section 4.5.1, Section 5.4.5(c), and / or other relevant sections provided herein.
[0892] The example was performed for AAV8 with the green fluorescent protein gene. Freeze-thaw cycles are used to simulate temperature changes in shipping and storage logistics, and can also act as an "accelerating" stress to force AAV degradation for formulation optimization work. like Figure 36 As shown, "modified dPBS with 4% sucrose" Formulation B (dark grey bars) maintained potency after 30 freeze-thaw cycles. In contrast, the reference formulation (dPBS, light grey bars) efficacy decreased to between 66% and 72% after 15 to 30 freeze-thaw cycles.
[0893]The shift to an acidic pH r...
example 10
[0900] 5.10 Example 10: Comparison of Physicochemical Properties of Formulations
[0901] This example shows the characterization of the physicochemical properties of different Construct II formulation buffer candidates, including pH, glass transition temperature (Tg'), osmolarity and density. Construct II is currently designed to be stored in a frozen formulation. The effect of freezing and freezer temperature fluctuations on buffer pH was investigated by tracking pH and temperature in real time using a cryogenic pH probe in a -20°C automatic defrost (-20°C AD) freezer. The phase transition of the formulations upon freezing and thawing was assessed by calorimetry. The results of this study indicate that pH changes of varying magnitudes depend on the formulation buffer composition, which is a key factor considering the importance of stable pH for long-term storage of pharmaceutical products. Additionally, the glass transition temperatures of the different formulation buffers...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com